Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.55 |
| ▸ | CLK2 | P49760 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801822 | 0.97 | PIK3CA (0.66) | PIK3CAMAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL28736417 | 0.94 | PIK3CA (0.57) | PIK3CAMAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL163906 | 0.91 | PIK3CA (0.75) | PIK3CAMAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL7168459 | 0.90 | CCNE2 (0.57) | PIK3CAMAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL7169729 | 0.85 | MAPT (0.54) | PIK3CAMAPTSMN1; SMN2CLK1CLK2 | |
| SCHEMBL13325954 | 0.84 | APP (0.67) | MAPTSMN1; SMN2CLK4APPTP53 | |
| SCHEMBL23431531 | 0.84 | MAPT (0.49) | PIK3CAMAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL13326070 | 0.84 | PDE4A (0.53) | PIK3CASMN1; SMN2NPC1 | |
| SCHEMBL27284393 | 0.84 | CLK4 (0.56) | PIK3CASMN1; SMN2CLK1CLK2DYRK1A | |
| SCHEMBL23431538 | 0.83 | MAPT (0.48) | PIK3CAMAPTSMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115737-B2 | Solid phase synthesis of novel biaryl triazine library by suzuki cross coupling | NEW YORK UNIVERSITY (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040225125-A1 | Solid phase synthesis of novel biaryl triazine library by suzuki cross coupling | NEW YORK UNIVERSITY (US) | 2004-11-11 | — | — | US | disclosed |
| US-6552018-B1 | As antitumor agents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-6169086-B1 | AN ANTITUMOR AGENT FOR TREATING TUMOR RESISTANT TO 5-FLUOROURACIL TYPE DRUGS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-1022270-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225125-A1 | Solid phase synthesis of novel biaryl triazine library by suzuki cross coupling | BOLA2; BOLA2B, BRDT, SBDS | PIK3CA 4110/4885MAPT 3155/4885SMN1; SMN2 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.